FDA Approved: ENSPRYNG — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for ENSPRYNG (satralizumab) submitted by Genentech, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica Spectrum Disorder

Drugs mentioned

• Enspryng (satralizumab)

Snippet

SUPPL AP for ENSPRYNG (SATRALIZUMAB)